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Editorial
Polycystic ovary syndrome (PCOS) affects about 5-10% of fertile
women and is characterised by insulin resistance (IR), dyslipidaemia,
hyperandrogenism, and oligomenorrhoe. The metabolic disruption in
PCOS women requires treatment to prevent the progression of IR to
diabetes and cardiovascular disease. Metformin is currently first line
treatment for metabolic/glycemic abnormalities, but lacks beneficial
effect on IR PCOS patients with side-effects and cost outweighing
benefits. Rosiglitazone has shown to reduce IR,but it was recently
withdrawn from the market due to severe side-effects. Basic research
into developing optimised drug treatments for IR in PCOS is critical to
reducing the development of PCOS associated diabetes and
cardiovascular disease. Testing and optimising drugs to reduce IR in
PCOS patient samples is difficult due to ethical restrictions. In vitro
organ culture models are valuable and reliable. Coronary arteries
incubated with high doses of insulin and glucose will be screened for
reliable intracellular IR associated biomarkers by western blot and real
time PCR analysis. Vascular function by wire-myograph analysis will
validate endothelial dysfunction and assess myocardial vascular injury
associated responses. The associated response to clinically relevant
anti-diabetic treatment options and adjunct therapy will be
investigated. Developing a PCOS IR simulated organ culture model
will enable us to understand the complicated intracellular signalling
mechanisms leading to IR and may lead to development of potential
new drug therapy options improving the PCOS IR treatment outcome.
Keywords: Polycystic ovary syndrome; Insulin resistance;
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Introduction and Epidemiology
The key features of PCOS is (i) dysfunctional insulin activity in
muscle, liver and adipose tissues leading to IR and hyperinsulinaemia
and (ii) intact insulin induced overproduction of androgens by theca
cells in the ovarian tissue causing hyperandrogenaemia. PCOSa
common endocrinopathy of complex etiology that produces
symptoms in about 5-10% of women during their reproductive years
[1].
Symptoms
The main symptoms of PCOS are anovulation, insulin resistance,
and hyperandrogenaemia.
Anovulation
Anovulation results in irregular menstrual pattern (e.g.
oligomenorrhea or amenorrhea) and infertility. The number of
primordial follicles is normal in women with PCOS, while primary
and secondary follicles are significantly increased. Anovulation occur
because of the lack of development of a dominant follicle [2,3]. The
disturbance in menstrual pattern is so common that about 85-90% of
women with oligomenorrhea have been linked to PCOS, while 30-40%
of women with amenorrhea have PCOS [4]. Anovulatory infertility
affects about 40% of women with PCOS and approximately 90-95% of
anovulatory women seeking help from infertility clinics have PCOS
[2].
Insulin resistance
Researchers are still trying to unravel the fundamental defects that
initiate PCOS. Studies during the recent years have revealed
intracellular defective mechanisms that initiate IR. In brief, insulin
binds to the insulin receptor of the muscle, liver and adipose tissue
cells, but is unable to trigger the downstream intracellular pathway.
Dysfunctional insulin pathways in PCOS includes impaired (i)
autophosphorylation of tyrosine residues on the β subunit of insulin
receptor and (ii) reduced phosphorylation and activation of
phosphoinositide-3 kinase (PI3K), which leads to a reduced (a)
phosphorylation and activation of protein kinase B (PKB), (b)
phosphorylation and inactivation of glycogen synthase kinase-3
resulting in glycogen-synthase activation and (c) translocation of
insulin-responsive glucose transporter-4 to the cell surface [5].
Hyperinsulinemia is found in about 80% of obese and 30-40% of lean
women with PCOS [6].
Hyperandrogenaemia
High levels of male hormones creates hormonal imbalance and
leads to hirsutism and acne, and in some cases hypermenorrhea.
Hirsutism and acne features may be explained by difference in
expression of 5α-reductase in the sebaceous gland and the hair follicle
and resulting higher dihydrotestosterone in the hair follicle [7]. Inspite
of IR at peripheral sites the ovary remains sensitive to insulin as
observed in PCOS women with both normal and high BMI [8-10]. The
action of insulin on the liver leads to a decrease in the production of
sex hormone binding globulin and insulin-like growth factor 1 binding
protein which results in an increase in unbound testosterone. Thus,
although the ovary is the major site of increased androgen production
in PCOS, IR itself may contribute to the overall androgen levels. In a
study by Azziz et. al. 2004 the clinical features of PCOS women with
androgen excess were hirsutism in 75.5% and acne in 14.2% [11].
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Diagnosis
Clinical assessment of PCOS involves (i) history-taking of the
patient with emphasis on menstrual pattern, acne, male hair growth,
breast development, obesity and occurrence/history of PCOS in near
family, (ii) gynecologic ultrasonography establishing "follicular arrest"
and (iii) blood tests determining the serum levels of androgens.
In 2003 a consensus workshop sponsored by the European Society
for Human Reproduction and Embryology and the American Society
for Reproductive Medicine in Rotterdam amended the National
Institutes of Health and National Institute of Child and Human
Development consensus criteria to include polycystic ovaries as a third
diagnostic marker and to allow for a diagnosis of PCOS if two of three
criteria are met after excluding other androgen excess or related
disorders, such as pituitary and adrenal dysfunction: (i) oligoovulation
and/or anovulation, (ii) excess androgen activity and (iii) gynecologic
ultrasound showing polycystic ovaries [12].
PCOS associated cardiovascular disease development
IR leads to endothelial- and mitochondrial- dysfunction [13], and
this may lead to development of cardiovascular diseases, such as
coronary atherosclerosis and coronary artery disease. A study by
Dahlgren et al. showed an increased relative risk of 7.4 of developing
myocardial infarction in PCOS women compared to age-matched
female subjects [14]. Furthermore, activation of PI3K and PKB
signalling pathways have been shown to be important risk salvage
proteins in cardiovascular diseases [15], thus emphasising the role and
importance of these key kinases in both IR and cardiovascular
diseases.
PCOS therapy options
Management of clinical manifestations of PCOS for (i) menstrual
irregularities and hirsutism includes oral contraceptives, (ii) androgen
excess includes spironolactone and finasteride and (iii) infertility
include clomiphene, laparoscopic ovarian drilling, gonadotropins, and
assisted reproductive technology.
It is estimated that 10-20% of women with PCOS develop diabetes
[16]. The effect of these drugs on reducing the IR by increasing the
glucose uptake and reducing hyperandrogenaemia are not optimal, as
the drugs with limited adverse effect (e.g metformin and chlomiphene)
only show limited improvement in insulin sensitivity, while drugs with
strong recovery of insulin sensitivity (e.g. rosiglitazone and
troglitazone) have demonstrated severe adverse effects (e.g. liver
failure and heart attack), and have therefore been withdrawn from the
market [17]. The intracellular mechanisms involved in the
manifestation of PCOS are slowly emerging including many of the
physiological and cellular aspects of PCOS, however, there is a severe
lack of understanding and subsequent studies designed to find optimal
and specific treatment for women with PCOS and IR.
In vitro insulin resistance organ culture model
There are limits and obstacles when investigating the underlying
signalling pathways of PCOS in patients, as the samples are difficult to
access due to ethical restrains and the number of samples is limited.
The use of relevant diabetic animal models is also problematic, as these
animals suffer extremely due to their condition. Therefore, it is
fundamental to develop a reliable, reproducible and easily modified
model that mimics the intracellular mechanisms of PCOS IR
condition. This IR organ culture model will make it possible to
investigate pathways and therapeutic influence in great detail. Previous
studies have shown that addition of the key risk factors for IR (high
dose of insulin and glucose) to foetal rat liver and lung tissue produces
a marked alteration of the underlying key cellular components
involved in IR, such as glycogen synthase activity and glycogen
production. These cellular alterations are observed in PCOS women
and diabetic patients as well [5,18,19]. Developing an IR organ culture
model in rat coronary arteries will allow investigation of altered
expression of intracellular key components observed during IR and
vascular (dys)function and the associated response to clinically
relevant anti-diabetic treatment options and adjunct therapy. Vascular
and endothelium (dys)function can be measured by wire-myograph
experiments, while intracellular key components can be studied by
western blot, immunohistochemistry and mRNA and microRNA real
time PCR analysis (Figure 1).
Figure 1: Overview of proposed insulin resistance organ culture
model study. Left anterior decending artery segments from female
sprague dawley rats will be incubated in organ culture with specific
high dose of insulin and glucose, with and without clinically
relevant anti-diabetic treatment options and adjunct therapy. Wire-
myograph system will be used for functional studies of the vessels,
while western blot and real time PCR analysis will be used for in
depth molecular biology studies of key intracellular pathway
components.
In addition to the IR perspective this IR organ culture model will
also allow the assessment of myocardial injury or cardioprotection by
measuring specific biomarkers of myocardial injury [20] and the
vascular tone altered through differential expression of specific G-
protein coupled receptors involved in myocardial injury development
[21].
Conclusion
Development of an IR organ culture model will optimise insulin
sensitivity therapy options in PCOS. The model will inform the
advancement of new therapy options or modulate existing treatments
with adjunct therapy, which will improve long-term outcome and life
quality of women with IR due to PCOS.
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